Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.

  • 08:54

The United States Patent and Trademark Office (USPTO), has issued a notice of allowance regarding patent application 11/603,819 and thus intends to approve Immunicum’s patent application to protect the Company’s core-technology in the U.S. market.

Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4977

Comments are closed.